đŸ”„ABT grĂžnne skifte Egypt, 30 milliarder kroner markedđŸ”„

Slettet bruker
ABT 13.04.2021 kl 14:14 1240

Aqua Bio Technology ASA: FĂžrste ordre fra DBK Pharmaceuticals S.A.E. bekreftet
10.3.2021 16:05:47 CET | Aqua Bio Technology ASA | Innsideinformasjon
Aqua Bio Technology ASA (ABT) inngikk i https://newsweb.oslobors.no/message/486539 en distribusjonsavtale med

DBK Pharmaceuticals S.A.E. (DBK) i Kairo, Egypt om distribusjon av hudpleieserien Moana Skincare. https://www.dbk-eg.com/ er et raskt voksende egyptisk selskap innen markedsfÞring og salg av eksklusive kosmetikkprodukter sÄ vel som andre forbruksvarer. Det egyptiske markedet for kosmetikk og personlig pleie er anslÄtt til om lag 30 milliarder kroner og har en hÞy vekst.

DBKs lansering av Moana er forsinket grunnet Corona-pandemien, men ABT har nÄ mottatt fÞrste ordre som bekrefter det videre samarbeidet mellom ABT og DBK. Lanseringen av hudpleieserien forventes Ä finne skje i Q4 etter at Moana Skincare serien er ferdig registrert og godkjent i henhold til lokalt regelverk.

NĂŠrmere opplysninger ved adm. direktĂžr Espen Kvale, telefon 9162 8092.

Aqua Bio Technology ASA (ABT) utvikler og kommersialiserer bĂŠrekraftig

bioteknologi for bruk i hudpleieprodukter. ABTs kosmetikkingredienser er svĂŠrt

effektive og de representerer et naturlig alternativ til tradisjonelle

ingredienser for kosmetikkindustrien. ABT markedsfĂžrer og selger dessuten

naturlige hudpleieprodukter utviklet av partnere til konsumenter og

profesjonelle brukere. Aqua Bio Technology er notert pÄ Euronext Expand.

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12.

Informasjonspliktig opplysning

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven § 5-12.

Kontakter
Redigert 01.05.2021 kl 11:39 Du mÄ logge inn for Ä svare
Slettet bruker
14.04.2021 kl 08:43 1114

Nesten ingen aksjer for salg? det blir trangt i dÞrene fram mot 30.04 Ärsresultatet. Netthandelen tar av nÄ, ogsÄ med det grÞnne skifte som pÄgÄr innen kosmetikkindustrien.

Slettet bruker
30.04.2021 kl 14:41 907

0.4.2021 11:24:16 CEST | Aqua Bio Technology ASA | Inside information

Aqua Bio Technology ASA - Primary insider Notification

HĂ„vard LindstrĂžm, Head of Business Development and primary insider of Aqua Bio
Technology ASA (the "Company"), has today purchased 11 600 shares at a price of
10.70 per share, through his wholly owned company Ice Capital AS. Following this
purchase, HĂ„vard LindstrĂžm and related parties will continue to hold 337 919
shares in the company, corresponding to an ownership stake of 1.83% of the total
outstanding shares in the Company.

For further information, please contact Espen Kvale, CEO, telephone +47 916 28
092.

This information is subject to the disclosure requirements in Regulation EU
596/2014 article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
effective and they provide the cosmetics industry with natural alternatives to
traditional ingredients. ABT is also marketing and distributing natural skin
care products developed by partners towards consumers and professional users.
ABT's focus on commercialization and development of natural ingredients and
natural skin care products has been, and will continue to be, an important part
of the company's strategy going forward. Aqua Bio Technology is listed on
Slettet bruker
01.05.2021 kl 13:19 764

Commercial update Aqua Bio Technology (ABT)
30.04.2021 08:33
https://newsweb.oslobors.no/message/531782


30.4.2021 08:33:04 CEST | Aqua Bio Technology ASA | Non-regulatory press
releases

Products series from DCP Dermosciense (DCP)

Seidr and Seidr Cliniq have now passed all safety studies, which means that the
Seidr series (39 products in total) will be ready for distribution and sale in
q2 2021. See the first pictures from the series in Appendix 1.



Sister brand from Moana Skincare - B Natural

B Natural is based on the same unique ingredients as Moana Skincare and has been
created to adapt the product to other markets, expanding the commercial reach of
the unique Moana product line. The B Natural series (21 products in total ) is
ready for distribution and sale in q2 2021. See the first pictures from the
series in Appendix 1.



Update on new e-commerce website for ABT

ABT is launching a new e-commerce website in q2of 2021 containing all ABT
skincare products for shareholder and certain customers and will have B2B log in
for ABT's distributors



Restorsea's commercialization of ABT's hatching fluid ingredient (Aquabeautine
XL)

ABT's US partner Restorsea has invested large sums -
https://ir.lifemd.com/press-release-details.php#/?newsId=2114190 for the
exclusive right to use ABT's hatching fluid ingredient as the main ingredient in
its own and licensed products. As informed 8 of February 2021 -
https://newsweb.oslobors.no/message/524073 Hydrafacial officially announced its
partnership with Restorsea and launched in Q1 2021 its new Restorsea Lip Fix Kit
which is based on ABT's hatching fluid ingredient (Aquabeautine XL).



LifeMD (former Conversion Labs) presented NavaMD -
https://ir.lifemd.com/press-release-details.php#/?newsId=2205885 and its
cooperation with Restorsea in Q1 2021 and ABT expecting that the NavaMD products

containing Aquabeautine XL -
https://ir.lifemd.com/press-release-details.php#/?newsId=2114190 will be
launched in the near future.



The positive trend from Restorsea's commercialization of ABT's proprietary
technology increases the likelihood that ABT will receive additional renewal
payment and increased revenue from the sale of ingredients and royalties.



Pre launch of ABT`s products

ABT is planning a pre-launch of ABT's products in q2 and shareholders that would
like to learn more about the products and participate in the pre-launch should
subscribe and register on ABT`s website -
https://aquabiotechnology.com/pages/subscription to receive examples of our new
products.

For further information, please contact CEO Espen Kvale, telephone +47 9162
8092.

* * *

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. ABT's focus on commercialization and development of natural
ingredients and natural skin care products has been, and will continue to be, an
important part of the Company's strategy going forward.
Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock
Exchange.

This information was considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. The stock exchange
announcement was published by HĂ„vard LindstrĂžm, Head of Business Development, on
30 April 2021, at 08.30 CES

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Espen Kvale, CEO, +47 916 28 092, espen.kvale@aquabiotech.no

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/514/655/Download%20announcement%2
0as%20PDF.pdf

ABT stock exchange message appendix 30 April 2021.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/514/654/ABT%20stock%20exchange%20
message%20appendix%2030%20April%202021.pdf